Market Place
Sourcing Support
Humacyte Realigns Non-U.S. Symvess Rights for Expansion
24 Apr 2026 //
GLOBENEWSWIRE
Humacyte Reveals 2025 Q4 & Year-End Financials, Business Update
27 Mar 2026 //
GLOBENEWSWIRE
Humacyte Appoints Rick Mcelheny As Svp Of Business Development
26 Mar 2026 //
GLOBENEWSWIRE
Humacyte Announces $20M Direct Stock Offering Pricing
19 Mar 2026 //
GLOBENEWSWIRE
Humacyte Secures Up to $77.5M Credit Facility With Hercules
16 Dec 2025 //
GLOBENEWSWIRE
Humacyte Unveils Q3 2025 Financials & Business Update
12 Nov 2025 //
GLOBENEWSWIRE
Humacyte Gets Symvess™ ECAT Approval from U.S. Defense Agency
08 Jul 2025 //
GLOBENEWSWIRE
Humacyte To Present Q2 Results And Corporate Update On August 13
12 Aug 2024 //
GLOBENEWSWIRE
Humacyte ATEV™ Meets Primary Endpoints In Phase 3 Trial
31 Jul 2024 //
GLOBENEWSWIRE
Humacyte Adds Bamforth And Jones To Board Of Directors
16 Jul 2024 //
GLOBENEWSWIRE
Humacyte ATEV Receives FDA`s RMAT Designation For PAD
01 Jul 2024 //
GLOBENEWSWIRE
CMS Issues ICD-10-PCS Codes For Humacyte’s Human Acellular Vessel™ (HAV™)
17 Jun 2024 //
GLOBENEWSWIRE
Humacyte to Present at the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Humacyte to Participate at Upcoming Investor Conferences in May
13 May 2024 //
GLOBENEWSWIRE
Humacyte To Present Q1 Results, Corporate Update On May 10
06 May 2024 //
GLOBENEWSWIRE
Humacyte to Host Virtual KOL Event Hemodialysis Access: A Crossroads of Care
26 Mar 2024 //
GLOBENEWSWIRE
Humacyte to Present 2023 Fourth Quarter & Year-End Financial Results & Provide
18 Mar 2024 //
GLOBENEWSWIRE
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
01 Mar 2024 //
GLOBENEWSWIRE
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
29 Feb 2024 //
GLOBENEWSWIRE
Humacyte Announces Pricing of $40.2 Million Public Offering of Common Stock
29 Feb 2024 //
GLOBENEWSWIRE
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Results
17 Nov 2023 //
GLOBENEWSWIRE
Humacyte to Present Third Quarter Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Humacyte to Present at the Cantor Global Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20
18 Sep 2023 //
GLOBENEWSWIRE
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma
11 Sep 2023 //
GLOBENEWSWIRE
Humacyte Second Quarter 2023 Financial Results and Business Update
14 Aug 2023 //
GLOBENEWSWIRE
Humacyte to Present Second Quarter Financial Results on August 14, 2023
07 Aug 2023 //
GLOBENEWSWIRE
Humacyte to Present at the Jefferies Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
Humacyte First Quarter 2023 Financial Results and Business Update
12 May 2023 //
GLOBENEWSWIRE
Humacyte Announces Publication in Lancet Regional Health - Europe Presenting
09 May 2023 //
GLOBENEWSWIRE
Humacyte to Present First Quarter Financial Results and Provide Corporate Update
05 May 2023 //
GLOBENEWSWIRE
Humacyte Announces Publication of Preclinical Study Comparing Human Acellular
18 Apr 2023 //
GLOBENEWSWIRE
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
Humacyte to Present Fourth Quarter and Full Year Financial Results
21 Mar 2023 //
GLOBENEWSWIRE
Humacyte to Present at Upcoming Investor Conferences in March
27 Feb 2023 //
GLOBENEWSWIRE
Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma
13 Dec 2022 //
GLOBENEWSWIRE
Humacyte Human Acellular Vesselâ„¢ (HAVâ„¢) Ukraine Humanitarian Results
01 Dec 2022 //
GLOBENEWSWIRE
Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
23 Nov 2022 //
GLOBENEWSWIRE
Humacyte Third Quarter 2022 Financial Results and Business Update
10 Nov 2022 //
GLOBENEWSWIRE
Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™)
07 Nov 2022 //
GLOBENEWSWIRE
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update
03 Nov 2022 //
GLOBENEWSWIRE
Humacyte Announces Presentations by Ukrainian Surgeons Human Acellular Vessel™
23 Sep 2022 //
GLOBENEWSWIRE
Humacyte Expands Board of Directors and Leadership Team with New Appointments
20 Sep 2022 //
GLOBENEWSWIRE
Humacyte Announces Presentation on Investigational Human Acellular VesselTM
09 Sep 2022 //
GLOBENEWSWIRE
Humacyte to Present Second Quarter 2022 Financial Results
05 Aug 2022 //
GLOBENEWSWIRE
Humacyte Preclinical Data on Small-Diameter HAV in CABG Presented at AHA
25 Jul 2022 //
GLOBENEWSWIRE
Humacyte to Present Preclinical Data on HAV in Coronary Artery Bypass Grafting
19 Jul 2022 //
GLOBENEWSWIRE
Humacyte Hosting Webinar on Human Acellular Vessels in Vascular Trauma
07 Jul 2022 //
GLOBENEWSWIRE
Humacyte Announces JAMA Surgery Publication Highlighting Potential of HAV
29 Jun 2022 //
GLOBENEWSWIRE
Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.
27 Jun 2022 //
GLOBENEWSWIRE
Humacyte Provides Update on Patients Treated at Hospitals in Ukraine with HAV
21 Jun 2022 //
GLOBENEWSWIRE
Humacyte Presents New Immunogenicity Data on Human Acellular Vessels
08 Jun 2022 //
GLOBENEWSWIRE
Humacyte to Present at the H.C. Wainwright Global Investment Conference
16 May 2022 //
GLOBENEWSWIRE
Humacyte First Quarter 2022 Financial Results and Business Update
13 May 2022 //
GLOBENEWSWIRE
Humacyte to Provide Human Acellular Vessels to Front-line Hospitals in Ukraine
09 May 2022 //
GLOBENEWSWIRE
Humacyte to Present First Quarter 2022 Financial Results
06 May 2022 //
GLOBENEWSWIRE
Humacyte Expands Leadership Team with Appointment of Shamik Parikh, M.D., as CMO
05 Apr 2022 //
GLOBENEWSWIRE
Humacyte Announces Date of Annual Shareholder Meeting
04 Apr 2022 //
GLOBENEWSWIRE
